FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Chikungunya Vaccine Suspended Due to Safety Concerns

[ Price : $8.95]

CBER suspends Valneva Austrias BLA for Ixchiq (chikungunya vaccine, live) due to serious safety concerns related to the vaccine.

FDA Study: CBD Linked to Elevated Liver Enzymes

[ Price : $8.95]

An FDA clinical trial finds that daily use of cannabidiol at levels typically used by consumers can cause elevated liver enzymes i...

Priority Review for Gamida sBLA for Omidubicel

[ Price : $8.95]

FDA accepts for priority review a Gamida Cell supplemental BLA for omidubicel and its use in severe aplastic anemia.

Breakthrough Status for Quests Haystack MRD Test

[ Price : $8.95]

FDA grants Quest Diagnostics a breakthrough device designation for its Haystack MRD test, a liquid biopsy designed to detect minim...

Alert on Hyperbaric Oxygen Devices

[ Price : $8.95]

FDA alerts health care providers and facilities about the safe use of hyperbaric oxygen therapy devices following reports of serio...

FDA Broadens Use of Amgens Repatha

[ Price : $8.95]

FDA expands the approved use of Amgens cholesterol-lowering drug Repatha (evolocumab) to include adults at increased risk of major...

Argenx Plans sBLA for Vyvgart in Myasthenia Gravis

[ Price : $8.95]

Argenx says it will seek expanded approval for Vyvgart (efgartigimod alfa-fcab) to include adults with acetylcholine receptor anti...

Vanda Urges Makary to Intercede in Generic Dispute

[ Price : $8.95]

Vanda Pharmaceuticals urges FDA commissioner Marty Makary to reconsider a recent agency decision upholding approvals of two generi...

AdvaMed Urges FDA/CMS Alignment on Breakthrough Devices

[ Price : $8.95]

AdvaMed and other device stakeholders urge the Centers for Medicare & Medicaid Services to overhaul how it covers new device techn...

Boston Scientific Recalls Defective Stent System

[ Price : $8.95]

Boston Scientific recalls (Class 1) its Carotid Wallstent Monorail Endoprosthesis due to a manufacturing defect that created an in...